Lilly China announced on Saturday the official opening of its innovation accelerator Lilly Gateway Laboratory (LGL) in Beijing, which is designed to enable the next generation of scientific breakthroughs through access and mentorship to Lilly scientists, executives and functional expertise.

LGL Beijing is the company's fourth facility of its kind and the first to open outside of the United States.

"China's biopharmaceutical market is rapidly evolving, with significant growth and a strong focus on innovation," said Huzur Devletsah, president and general manager of Lilly China.

"As one of the world's leading healthcare markets and an emerging biotech research and development hub, China offers an ideal setting for scientific advancements, and LGL Beijing will play a crucial role in integrating Lilly's efforts with China's healthcare ecosystem through translational research, incubation and partnerships," she said.

LGL Beijing is tailored to support early-stage biotech enterprises, merging Lilly's scientific expertise with operational excellence to create a world-class research environment. Also, it will be the first LGL site to offer data analysis space for advanced technology and machine learning biotech enterprises. It is expected to accommodate five to eight biotech enterprises.

Julie Gilmore, vice-president and global head of LGL & Catalyze360 Portfolio Management, said, "Our expansion in Beijing will enable leading Chinese biotech enterprises to access unparalleled scientific engagement and strategic counsel from Lilly to accelerate their development of innovative medicines for the future."

On the same day, LGL Beijing welcomed its first tenant, 4B Technologies, which is dedicated to R&D of innovative medicines for neurodegenerative and other neurological disorders.